Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Aptima HPV E6/E7 mRNA and cytology cross-sectional performance as primary screening tests for detection of high-grade cervical lesions in HIV positive and negative women in South Africa.
J Med Screen
February 2025
Department of Obstetrics and Gynaecology, Stellenbosch University, Stellenbosch, South Africa.
Objective: To assess the performance of APTIMA HPV E6/E7 mRNA assay (AHPV) with HPV 16 and 18/45 genotyping (AHPV-GT) and cytology in detecting cervical cancer and precancer in HIV positive and negative women in South Africa.
Methods: A multicentre cross-sectional study was performed in women aged 25-64 (n = 992) with cytology and AHPV with AHPV-GT reflex testing. All screen-positive and a random subset of screen-negative women were referred for colposcopy and biopsy.
Using electronic health records to evaluate the adherence to cervical cancer prevention guidelines: A cross-sectional study.
Prev Med
June 2024
Institute of Computer Science, University of Tartu, Narva mnt 18, 51009 Tartu, Estonia. Electronic address:
Objective: The fight against cervical cancer requires effective screening together with optimal and on-time treatment along the care continuum. We examined the impact of cervical cancer testing and treatment guidelines on testing practices, and follow-up adherence to guidelines.
Methods: Data from Estonian electronic health records and healthcare provision claims for 50,702 women was used.
Value of a catch-up HPV test in women aged 65 and above: A Danish population-based nonrandomized intervention study.
PLoS Med
July 2023
University Research Clinic for Cancer Screening, Department of Public Health Programmes, Randers Regional Hospital, Randers, Denmark.
Background: High-risk human papillomavirus (HPV) test is replacing cytology as the primary cervical cancer screening test due to superior sensitivity, but in most countries women ≥65 years have never had an HPV test despite they account for around 50% of cervical cancer deaths. We explored the effect of a catch-up HPV test among 65- to 69-year-old women without previous record of HPV-based screening.
Methods And Findings: This population-based nonrandomized intervention study (quasi-experimental design) included Danish women aged 65 to 69 with no record of cervical cancer screening in the last ≥5.
[Chinese expert consensus on the use of human papillomavirus nucleic acid testing for cervical cancer screening (2022)].
Zhonghua Yi Xue Za Zhi
April 2023
China is currently in a critical period of accelerating the elimination of cervical cancer, and scaling up screening coverage with high-quality methods is one of the main approaches to achieve this goal. World Health Organization (WHO) recommended human papillomavirus (HPV) nucleic acid testing as the preferred primary screening method of cervical cancer. However, no guidelines exist for its use in cervical cancer screening in China.
View Article and Find Full Text PDFSecondary Prevention of Cervical Cancer: ASCO Resource-Stratified Guideline Update.
JCO Glob Oncol
September 2022
National Cancer Institute, Bethesda, MD.
Purpose: To update resource-stratified, evidence-based recommendations on secondary prevention of cervical cancer globally.
Methods: American Society of Clinical Oncology convened a multidisciplinary, multinational Expert Panel to produce recommendations reflecting four resource-tiered settings. A review of existing guidelines, formal consensus-based process, and modified ADAPTE process to adapt existing guidelines was conducted.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!